Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 11/20 | 0.49 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | IDH2 | P48735 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4234991 | 0.96 | THRB (0.54) | THRBKDREGFRTNNI3KKDM4E | |
| SCHEMBL690055 | 0.85 | EGFR (0.53) | EGFRTNNI3KKDM4EMEN1MAPT | |
| SCHEMBL4235267 | 0.85 | AURKA (0.55) | THRBKDREGFRTNNI3KKDM4E | |
| SCHEMBL2778932 | 0.83 | EGFR (0.53) | KDREGFRTNNI3KKDM4EMEN1 | |
| SCHEMBL4234986 | 0.83 | AURKA (0.55) | THRBKDREGFRTNNI3KKDM4E | |
| SCHEMBL4239042 | 0.82 | THRB (0.68) | THRBEGFRTNNI3KKDM4EERBB4 | |
| SCHEMBL13777945 | 0.80 | EGFR (0.74) | THRBKDREGFRKDM4EERBB4 | |
| SCHEMBL13777940 | 0.78 | EGFR (0.74) | THRBKDREGFRKDM4EERBB4 | |
| SCHEMBL1387447 | 0.77 | THRB (0.80) | THRBEGFRTNNI3KKDM4EERBB4 | |
| SCHEMBL13778007 | 0.73 | THRB (1.00) | THRBKDREGFRTNNI3KKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC | 2009-07-16 | — | — | US | claimed |
| EP-1943233-A2 | COMPOUNDS AND COMPOSITIONS FOR PROTEIN KINASE INHBITORS | IRM, LLC (BM) | 2008-07-16 | — | — | EP | claimed |
| WO-2007056151-A2 | PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2007-05-18 | — | — | WO | claimed |
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC | 2009-07-16 | — | — | US | disclosed |
| EP-1943233-A2 | COMPOUNDS AND COMPOSITIONS FOR PROTEIN KINASE INHBITORS | IRM, LLC (BM) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007056151-A2 | PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ERBB2, BMX, ERBB3 | THRB 461/4885KDR 116/4885EGFR 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.